Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gedatolisib plus Talazoparib in advanced TNBC or BRCA1/2+ HER2- breast cancer
NCT03911973Phase 2Active, not recruiting
- Sponsor
- Kari Wisinski
- Start
- Apr 2019
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gedatolisib in triple negative breast cancer (TNBC), breast cancer, sponsored by Kari Wisinski. Started Apr 2019; status: active, not recruiting.
02
Drugs
gedatolisib
03
Conditions
triple negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on NCT03911973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03911973.